On April 12, Jiangsu Hengrui Medicine Co.Ltd(600276) ( Jiangsu Hengrui Medicine Co.Ltd(600276) . SH) announced that Zou Jianjun, deputy general manager of the company, resigned for personal reasons. Meanwhile, Jiangsu Hengrui Medicine Co.Ltd(600276) announced the appointment of Zhang Xiaojing as deputy general manager and Chief Medical Executive Officer (Oncology) and Wang Quanren as deputy general manager.
For the appointment of new executives, Jiangsu Hengrui Medicine Co.Ltd(600276) deputy general manager Zhang Lianshan, President of global R & D, said: “we are very glad that Zhang Xiaojing and Wang Quanren have joined the Jiangsu Hengrui Medicine Co.Ltd(600276) senior management team, which is also a further embodiment of the specialization of management talents in our R & D field. Their promotion will help Jiangsu Hengrui Medicine Co.Ltd(600276) further strengthen internal R & D and innovation capabilities, accelerate the pace of innovation, and bring new impetus to the realization of Jiangsu Hengrui Medicine Co.Ltd(600276) ‘focus on innovation and build a Multinational Pharmaceutical Group’.”
Over the past year, Jiangsu Hengrui Medicine Co.Ltd(600276) has performed poorly in the capital market and its share price has been falling all the way. As of the closing on April 12, Jiangsu Hengrui Medicine Co.Ltd(600276) share price is 33.67 yuan / share, and the current total market value is about 215 billion yuan. In January 2021, Jiangsu Hengrui Medicine Co.Ltd(600276) share price reached the highest 116.87 yuan / share.
Under the pressure of the share price in the capital market, Jiangsu Hengrui Medicine Co.Ltd(600276) continues to increase its investment in R & D and innovation. In 2020 Jiangsu Hengrui Medicine Co.Ltd(600276) R & D expenses will be 4.989 billion yuan. In the first three quarters of 2021, Jiangsu Hengrui Medicine Co.Ltd(600276) R & D expenses amounted to 4.142 billion yuan, accounting for 20.51% of operating revenue, with a year-on-year increase of 23.86%.
According to Jiangsu Hengrui Medicine Co.Ltd(600276) announcement, Zhang Xiaojing, born in 1977, graduated from Peking Union Medical College and Cancer Hospital of Chinese Academy of Medical Sciences. In 2007, he joined Novartis pharmaceutical and served as the medical director of some products in the field of cancer, responsible for the clinical research and application for listing of some tumor products in China and other Asia Pacific regions. From 2009 to 2019, he worked in Bayer pharmaceutical global R & D Center (China and the United States), and successively served as senior medical expert and global clinical R & D director of some products in the field of cancer. .
Wang Quan, born in 1986, graduated from Shanghai Institute of pharmacy, Chinese Academy of Sciences in 2013 with a doctorate. In 2014, he joined Jiangsu Hengrui Medicine Co.Ltd(600276) , engaged in the clinical development of new antitumor drugs, and successively served as medical manager, deputy medical director and medical director, during which he presided over the clinical development of multiple class 1 new drugs and combined drugs. From 2021 to now, he has served as the deputy general manager of the subsidiary, in charge of clinical medicine, clinical pharmacology, clinical statistics and other affairs.
Jiangsu Hengrui Medicine Co.Ltd(600276) relevant person in charge said, Jiangsu Hengrui Medicine Co.Ltd(600276) has long respected the value of talents, regarded attracting and cultivating talents as an important talent strategy to promote the sustainable development of enterprises, continuously strengthened talent capacity-building and talent reserve training plan, and comprehensively promoted the layout of innovative and international talents. In recent years, the company’s R & D strength has been continuously strengthened, and the proportion of R & D personnel in the total number of employees has remained stable, providing strong talent support for continuously promoting scientific and technological innovation and international development strategy Jiangsu Hengrui Medicine Co.Ltd(600276) has established R & D centers or branches in the United States, Europe, Australia, Japan and China, and built a relatively perfect research institutions and talent echelon around the discovery, development, clinical research and registration of innovative products. These professional, comprehensive and well structured innovative drug R & D teams have become a strong guarantee for the continuous and stable completion of the innovation plan, The company’s innovative R & D work can be carried out steadily and efficiently.
It is reported that at present, there are 10 innovative drugs listed in Jiangsu Hengrui Medicine Co.Ltd(600276) China, more than 50 innovative drugs are under clinical development, and more than 240 clinical trials are carried out outside China. Among them, 25 innovative drug projects have been approved to carry out global multi center or regional clinical research, of which 8 are international multi center phase III projects, and a number of studies are in the preparation stage. A total of 86 overseas centers have been launched Jiangsu Hengrui Medicine Co.Ltd(600276) has built a number of technology platforms with independent intellectual property rights, covering the world’s cutting-edge technology fields and forming an echelon of product pipelines. It has rich R & D pipelines in the field of cancer, covering a wide range of research fields such as kinase inhibitors, antibody drug conjugates (ADC), tumor immunity, hormone receptor regulation, DNA repair and epigenetic, supportive treatment and so on. At the same time, Jiangsu Hengrui Medicine Co.Ltd(600276) has also made extensive layout in non-tumor fields such as autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory diseases, blood diseases and nervous system diseases.
